[an error occurred while processing this directive] | [an error occurred while processing this directive]
Combined use of NLR, V20 and Dmean to predict radiation-induced lung injury in lung cancer patients:an external validation study
Pan Wenyan, Kong Wei, Wang Yanyyang, Hai Ping, Bai Xuehong, Bai Zhoulan, Lu Haiyang, Zhao Ren
Department of Radiation Oncology, Tumor Hospital and General Hospital of Ningxia Medical University;Clinical Cancer Research Center of Ningxia, Yinchuan 750004, China
AbstractObjective To externally validate the accuracy of combined use of neutrophil-lymphocyte ratio (NLR),V20,and Dmean in predicting the incidence of grade Ⅲ or higher radiation-induced lung injury (RILI) in lung cancer patients.Methods A total of 166 lung cancer patients, who participated in the model establishment were selected into the internal validation group, and 85 lung cancer patients who received intensity-modulated radiotherapy in our department between June 2016 and June 2018 were assigned into the external validation group. The incidence rate of grade 3 or higher RILI was statistically compared between the internal and external validation groups. Multivariate logistic analysis was performed for NLR, V20 and Dmean. The discrimination degree of the predictive model was evaluated by using ROC curve in combination with NLR, V20 and Dmean. The calibration degree of the predictive model was assessed by Hosmer-Lemeshowtest.Results The incidence rate of grade 3 or higher RILI in the internal and external validation groups was 23.8% and 22.9%. Multivariate logistic analysis demonstrated that NLR, V20 and Dmean significantly differed in the internal validation group (P=0.032, 0.006 and 0.005). However, only V20 significantly differed in the external validation group (P=0.038). The discrimination and calibration degree of RILI was almost consistent between the internal and external validation groups (both P>0.05). The area under the curve (AUC) predicted by NLR, V20, Dmean and the combination of three indexes were 0.611, 0.646, 0.682 and 0.775 in the internal validation group, and 0.544, 0.702, 0.658 and 0.754 in the external validation group, respectively. The calibration degree in the internal validation group was P=2.797 and 0.834, P=2.452 and 0.653 in the external validation group. Conclusion Combined application of NLR, V20 and Dmean can accurately predict the incidence of grade Ⅲ or higher RILI in lung can cancer patients, which has been validated by external dataset.
Pan Wenyan,Kong Wei,Wang Yanyyang et al. Combined use of NLR, V20 and Dmean to predict radiation-induced lung injury in lung cancer patients:an external validation study[J]. Chinese Journal of Radiation Oncology, 2019, 28(6): 417-420.
Pan Wenyan,Kong Wei,Wang Yanyyang et al. Combined use of NLR, V20 and Dmean to predict radiation-induced lung injury in lung cancer patients:an external validation study[J]. Chinese Journal of Radiation Oncology, 2019, 28(6): 417-420.
[1] 毛艳,刘文其.放射性肺损伤防护的研究进展[J].肿瘤,2012,30(5):389-394.DOI:10.3781/j.issn.1000-7431.2012.05.015. Mao Y,Liu QW.Research progress on protection of radioactive lung injury[J].Oncology,2012,30(5):389-394. DOI:10.3781/j.issn.1000-7431.2012.05.015. [2] Pan WY,BianC,ZouGL,etal. Combing NLR,V20 and mean lung dose to predict radiation induced lung injury in patients with lung cancer treated with intensity modulated radiation therapy and chemotherapy[J].Oncotarget,2017,8(46):81387-81393.DOI:10.18632/oncotarget.19032. [3] Bradley JD,PaulusR,KomakiR,etal. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stageⅢA or ⅢB non-small-cell lung cancer (RTOG 0617):a randomised,two-by-two factorial phase 3 study[J].Lancet Oncol,2015,16(2):187-199.DOI:10.1016/S1470-2045(14)71207-0. [4] TrottiA,ColevasAD,SetserA,etal. CTCAE v3.0:development of a comprehensive grading system for the adverse effects of cancer treatment[J].SeminRadiatOncol,2003,13(3):176-181. DOI:10.1016/S1053-4296(03)00031-6. [5] 姬巍,王绿化,欧广飞,等.非小细胞肺癌术后适形放疗肺损伤相关因素研究[J].中华放射肿瘤学杂志,2009,18(4):274-277.DOI:10.3760/cma.j.issn.1004-4221.2009.04.274. Ji W,WangLH,OuGF,et al. Study on the related factors of lung injury in conformal radiotherapy after operation of non-small cell lung cancer[J].Chin J Radiat Oncol,2009,18(4):274-277. DOI:10.3760/cma.j.issn.1004-4221.2009.04.274. [6] Marks LB,BentzenSM,DeasyJO,etal. Radiationdosevolumeeffects in the lung[J].Int J RadiatOncolBiol Phys,2010,76(3Suppl):S70-76.DOI:10.1016/j.ijrobp.2009.06.091. [7] Wang H,ZhangB,ChenD,etal. Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer[J].Clin Epigenetics,2015,7(1):119.DOI:10.1186/s13148-015-0150-9. [8] Kong FM,WangS.Nondosimetric risk factors for radiation-induced lung toxicity[J].SeminRadiatOncol,2015,25(2):100-109.DOI:10.1016/j.semradonc.2014.12.003. [9] Kiriu T,YamamotoM,NaganoT,etal. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer[J].PLoS One,2018,13(2):e0193018.DOI:10.1371/journal.pone.0193018. [10] MishalianI,GranotZ,FridlenderZG.The diversity ofcirculating neutrophils in cancer[J].Immunobiology,2017,222(1):82-88.DOI:10.1016/j.imbio.2016.02.001.
2019, Vol. 28 
